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Inter-rater reliability of STOPP (Screening
Tool of Older Persons’ Prescriptions) and
START (Screening Tool to Alert doctors to
Right Treatment) criteria amongst
physicians in six European countries
SIR—Inappropriate prescribing (IP) encompasses the use
of medicines where the risk of an adverse drug event (ADE)
outweighs the clinical benefit, particularly when safer ormore
effective alternatives are available [1, 2]. IP also includes
the use of medicines that increase the likelihood of drug–
drug and drug–disease interactions, the mis-prescribing of
medicines (incorrect dose, frequency and duration) and the
under-use of clinically indicated medicines [3–5]. IP is highly
prevalent in older people and has been associated with pre-
ventable ADEs, hospitalisation, institutionalisation, death
and resource wastage [6–12]. With increasing proportions
of older people worldwide, quality and safety of prescribing
are becoming a global healthcare concern [5, 13].
One way of identifying IP is to use prescribing indicators
such as the recently validated STOPP (Screening Tool of
Older Persons’ Prescriptions) and START (Screening Tool
to Alert doctors to Right Treatment) criteria [14]. STOPP
comprises 65 indicators for potentially inappropriate pre-
scribing including drug–drug and drug–disease interactions,
therapeutic duplication and drugs that increase the risks of
cognitive decline and falls (Appendix 1 in the supplemen-
tary data at Age and Ageing online) [14]. START incorporates
22 evidence-based indicators for prescribing omissions in
older people (Appendix 2 in the supplementary data at Age
andAgeing online) [14]. STOPP/START criteria are organised
according to physiological systems for ease of use. Their con-
tent validity was established by aDelphi consensus process in
which 18 experts in geriatric pharmacotherapy from Ireland
and the United Kingdom participated [14]. A recent study
showed that 35% of 715 acutely ill older patients requiring
hospitalisation were regularly prescribed at least one poten-
tially inappropriate medication according to STOPP criteria
and 12% of admissions were directly attributable to associ-
ated serious ADEs [15]. Another study of 600 older patients
showed that 58% were not prescribed clinically indicated
medications without contraindication according to START
criteria [16].
Prospective randomised controlled trials are needed to
test whether routine clinical application of STOPP/START
criteria can significantly improve prescribing appropriate-
ness and reduce drug-related morbidity. However, before
demonstrating effects on patient outcome, a screening tool
must be generalisable and reliable. Inter-rater reliability of
STOPP/STARTcriteriawas substantialwhen testedbetween
two researchers (kappa coefficient 0.75 STOPP criteria and
0.68 START criteria) [14]. Further evaluation of reliability
between health professionals practicing in different coun-
tries is warranted to determine if STOPP/START criteria
are generalisable. Accordingly, the aim of this study was to
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determine the inter-rater reliability of STOPP and START
criteria between multiple physicians practicing in different
European centres.
Methods
Twenty datasets were selected from a cohort of 200 consec-
utive patients aged ≥65 years admitted acutely to the general
medical services of a university teaching hospital in Ireland
whowereparticipating in a concurrent randomised controlled
trial designed to evaluate the effect of an intervention on
prescribing appropriateness. The 20 datasets were specifi-
cally selected to represent patients with complex comorbidi-
ties and an appreciable incidence of potentially inappropriate
prescriptions according to STOPP/START criteria. Ethical
approval was obtained for anonymous use of these datasets
in this inter-rater reliability study.
Each dataset was compiled from chart review and patient
and/or carer interview at the timeof hospitalisation,with sup-
plementary information on diagnoses and prescriptions being
sought from the patient’s general practitioner and/or com-
munity pharmacist when required. Datasets comprised age,
gender, current and past diagnoses, detailed medication his-
tory, drug allergies, bloodpressure profile, electrocardiograph
results, serum biochemistry, glucose, lipid profile, urinalysis
and estimated creatinine clearance using theCockcroft–Gault
equation [17], chosen instead of the Modified Diet in Renal
Disease formula [18–20] as the latter is not well validated in
patients aged >70 years [20–22].
The 20 patients’ mean (±SD) age was 76.8 (±5.4) years,
and 50% were female. The total number of prescribed med-
ications was 181, median 9, interquartile range 6–11. Two
of the STOPP/START originators (PG, DO’M) from the
coordinating centre in Ireland discussed the 20 datasets in
detail and reached complete agreement in terms of prescrib-
ing appropriateness according to STOPP/START criteria.
This combined level of agreement (labelled ‘rater 1’) was set as
the standard against which other physicians’ ratings would be
compared.Nineteen datasets had at least one potentially inap-
propriate prescription according to STOPP criteria (median
2; range 0–5). Eleven datasets had at least one prescribing
omission according to START criteria (median 1; range 0–4).
Eight hospital physicians (labelled ‘raters 2–9’) with no
prior experience of using STOPP/START criteria partici-
pated in the study. These physicians were based in teaching
hospital geriatric medicine units in Belgium (n = 1), Czech
Republic (n = 2), Italy (n = 3), Spain (n = 1) and Switzerland
(n = 1). STOPP/START criteria were translated from
English into Czech, French, Italian and Spanish (available
on request from the corresponding author) to facilitate local
application of the criteria. The 20 datasets were also trans-
lated. A teleconference facilitated by the coordinating cen-
tre in Ireland afforded all raters the opportunity to resolve
any difficulties with translation or interpretation of the cri-
teria before application. Two criteria were clarified: (i) ther-
apeutic and maintenance doses of proton pump inhibitors
Table 1. Inter-rater reliability of STOPP and START criteria
between 9 hospital physicians on 20 datasets with 181
medications
Rater combination A B C D Ppos Pneg Kappa (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
STOPP criteria
Rater 1 ∗ rater 2 1,255 4 0 41 0.99 0.95 0.95 (0.91–0.99)
Rater 1 ∗ rater 3 1,254 5 3 38 0.99 0.90 0.90 (0.83–0.97)
Rater 1 ∗ rater 4 1,254 5 3 38 0.99 0.90 0.90 (0.83–0.99)
Rater 1 ∗ rater 5 1,255 4 0 41 0.99 0.95 0.95 (0.91–0.99)
Rater 1 ∗ rater 6 1,258 1 2 39 0.99 0.96 0.96 (0.92–1)
Rater 1 ∗ rater 7 1,257 2 1 40 0.99 0.96 0.96 (0.92–1)
Rater 1 ∗ rater 8 1,253 6 3 38 0.99 0.89 0.89 (0.82–0.96)
Rater 1 ∗ rater 9 1,250 9 0 41 0.99 0.90 0.90 (0.83–0.96)
Median (IQR) 0.99 0.93 0.93 (0.90–0.96)
START criteria
Rater 1 ∗ rater 2 417 3 2 18 0.99 0.88 0.87 (0.76–0.98)
Rater 1 ∗ rater 3 417 3 3 17 0.99 0.85 0.84 (0.72–0.97)
Rater 1 ∗ rater 4 418 2 1 19 0.99 0.92 0.92 (0.84–1)
Rater 1 ∗ rater 5 417 3 0 20 0.99 0.93 0.93 (0.84–1)
Rater 1 ∗ rater 6 416 4 3 17 0.99 0.83 0.82 (0.69–0.95)
Rater 1 ∗ rater 7 415 5 5 15 0.98 0.75 0.74 (0.58–0.89)
Rater 1 ∗ rater 8 413 7 1 19 0.99 0.83 0.82 (0.69–0.94)
Rater 1 ∗ rater 9 414 6 0 20 0.99 0.87 0.86 (0.75–0.97)
Median (IQR) 0.99 0.86 0.85 (0.82–0.91)
A, both raters agreed criterion not fulfilled; B, rater 1 scored criterion not fulfilled
and rater 2 scored criterion as being fulfilled; C, rater 1 scored criterion as fulfilled
and rater 2 scored criterion as not fulfilled; D, both raters scored criterion as
being fulfilled; ppos, proportion of positive agreement; pneg, proportion of
negative agreement; CI, confidence interval; IQR, interquartile range.
(STOPP C4) and (ii) inclusion criteria for drug-class duplica-
tion (STOPP J1). All physicians then independently assessed
the incidence of 65 STOPP and 22 START criteria in each
of the 20 datasets and were invited to give written comments
if necessary.
Responses of raters 2–9 were cross-tabulated with those
of rater 1. Inter-group responses between physicians from
Italy and the Czech Republic were also evaluated, to deter-
mine reliability independent of the STOPP/START origina-
tors. Data were analysed using SPSS 15.0 forWindows (SPSS
Inc., Chicago, IL, USA). Inter-rater reliability analysis using
the kappa statistic (chance corrected measure of agreement)
was performed to determine consistency between raters [23].
The kappa statistic was interpreted as poor if ≤0.2, fair if
0.21–0.40, moderate if 0.51–0.6, substantial if 0.61–0.8 and
good if 0.81–1.00 [23]. Proportions of positive and negative
agreements were calculated [24]. Written comments were
analysed to determine whether disagreements were due to
misjudgement of appropriateness, difficulty with criteria or
case interpretation.
Results
Columns A, B, C and D in Tables 1 and 2 indicate the sta-
tus of agreement between raters. For example, raters 1 and
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Table 2. Inter-rater reliability of STOPP and START
between three physicians from Italy (raters 3, 4 and 5) and
two physicians from the Czech Republic (raters 6 and 7) on
20 datasets with 181 medications
Rater combination A B C D Ppos Pneg Kappa (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
STOPP criteria
Rater 3 ∗ rater 4 1,257 0 0 43 1.00 1.00 1.00 (NA)
Rater 3 ∗ rater 5 1,253 4 2 41 0.99 0.93 0.93 (0.87–0.99)
Rater 4 ∗ rater 5 1,253 4 2 41 0.99 0.93 0.93 (0.87–0.99)
Rater 6 ∗ rater 7 1,257 3 1 39 0.99 0.95 0.95 (0.90–0.99)
START criteria
Rater 3 ∗ rater 4 418 2 1 19 0.99 0.93 0.92 (0.84–1.00)
Rater 3 ∗ rater 5 415 5 2 18 0.99 0.84 0.83 (0.71–0.95)
Rater 4 ∗ rater 5 416 3 1 20 0.99 0.91 0.90 (0.81–0.99)
Rater 6 ∗ rater 7 413 4 7 16 0.99 0.74 0.73 (0.58–0.88)
A, both raters agreed criterion not fulfilled; B, rater 1 scored criterion not fulfilled
and rater 2 scored criterion as being fulfilled; C, rater 1 scored criterion as fulfilled
and rater 2 scored criterion as not fulfilled; D, both raters scored criterion as
being fulfilled; ppos, proportion of positive agreement; pneg, proportion of
negative agreement; CI, confidence interval; NA, not applicable.
2 agreed that STOPP criteria were not identified in 1,255
instances (column A). In four instances, rater 1 did not iden-
tify a STOPP criterion, but rater 2 did (column B). There
were no instances where rater 2 identified a STOPP criterion
that rater 1 did not (column C). In 41 instances, both raters 1
and 2 identified a STOPP criterion (column D). The median
(IQR) kappa coefficient between raters was 0.93 (0.90–
0.96) for STOPP criteria and 0.85 (0.82–0.91) for START
criteria.
Disagreement occurred with six STOPP criteria. Two
raters disagreed that aspirin was potentially inappropriate
without coronary, cerebral or peripheral arterial occlusive
symptoms or risk factors (STOPPA13). Three ratersmisclas-
sified second-generation antihistamines as first-generation
antihistamines (STOPP B13 and H3). Loop diuretics were
prescribed without indication in four cases; however, six
raters inferred an indication of ankle oedema or hyperten-
sion, thereby resulting in disagreement over STOPP cri-
teria A2 and A3. A typical neuroleptic was deemed inap-
propriate by one rater (STOPP B8), although it was pre-
scribed for behavioural and psychological symptoms of
dementia.
One rater judged it appropriate to omit a statin in one
patient with coronary artery disease (START A5) and severe
heart failure, as it was ‘unlikely to alter outcome’. Four raters
did not apply this criterion, as they ‘did not have sufficient
clinical information to measure life expectancy’. Two raters
wanted more clinical details before applying the START cri-
terion C2 (anti-depressant with depressive symptoms lasting
>3months) andSTARTcriterionE1 (diseasemodifying anti-
rheumatic drug with moderate–severe rheumatoid arthritis).
Five raters identified the START criterion D2 (fibre supple-
ment for chronic symptomatic diverticular disease with con-
stipation) in two patients with chronic constipation, though
diverticular disease was not specifically documented. Med-
ications without indication were sometimes interpreted as
indicating an underlying disease for which another medica-
tion was omitted e.g. one rater interpreted nitrate use as indi-
cating underlying angina and recommended a beta-blocker
(START A8).
Discussion
Inter-rater reliability of STOPP/STARTcriteria is goodwhen
tested between multiple physicians across six European cen-
tres. Themore comprehensive clinical andmedication details
used in this study are likely to account for the higher level of
inter-rater reliability than reported previously [14]. Disagree-
ments in a minority of instances reflected the fact that details
on functional status and life expectancy were not provided
with the cases, though clearly, these are important consider-
ations when applying STOPP/START criteria. Differences
in prescribing guidelines and formularies between countries
could cause disagreement with STOPP/START criteria, but
no physician in this study reported this.
A high level of familiarity is required to efficiently apply
‘pencil and paper’ versions of STOPP/START criteria in
clinical practice. This reality emphasises the need for com-
puterised automation of STOPP/START whereby linkage
of specific diseases or symptoms with specific medicines
would lead to rapid identification of potentially inappropri-
ate prescriptions according to STOPP criteria and omission
of indicated drugs according to START criteria. The good
inter-rater reliability demonstrated by this study indicates that
results of studies on the prevalence of potentially inappro-
priate prescribing identified by STOPP/START criteria are
comparable between countries.
Key points
 Inter-rater reliability of STOPP and START criteria is
good when tested between multiple physicians practicing
independently in different European centres.
 STOPP and START criteria are generalisable across dif-
ferent European countries and languages.
Conflicts of interest
No conflicts of interest.
Funding
Health Research Board of Ireland (Clinical Research Train-
ing Fellowship CRT/2006/029) and the Czech Ministry of
Health Internal Grant Agency (Grant Number 10029-4).
605
Research letters
Supplementary data
Supplementary data are available online at Age and Ageing
online.
PAUL GALLAGHER1,∗, JEAN-PIERRE BAEYENS2, EVA TOPINKOVA3,
PAVLA MADLOVA3, ANTONIO CHERUBINI4,
BEATRICE GASPERINI4, ALFONSO CRUZ-JENTOFT5,
BEATRIZ MONTERO5, PIERRE OLIVIER LANG6,
JEAN-PIERRE MICHEL6, DENIS O’MAHONY1
1Department of Geriatric Medicine, Cork University Hospital,
Wilton, Cork, Ireland
2Department of Geriatric Medicine, AZ Damiaan Oostende,
Oostende, Belgium
3Department of Geriatric Medicine, First Faculty of Medicine,
Charles University, Prague, Czech Republic
4Department of Clinical and Experimental Medicine, Institute of
Gerontology and Geriatrics, University of Perugia Medical School,
Perugia, Italy
5Servicio de Geriatria, Hospital Universitario Ramo´n y Cajal,
Madrid, Spain
6Rehabilitation and Geriatric Department, Geneva Medical
School and University Hospitals, Geneva, Switzerland
Email: pfgallagher77@eircom.net
∗To whom correspondence should be addressed
References
1. Beers MH, Ouslander JG, Rollinger I, Brooks J, Reuben D,
Beck JC. Explicit criteria for determining inappropriate med-
ication use in nursing homes. Arch Intern Med 1991; 151:
1825–32.
2. BeersMH.Explicit criteria for determining potentially inappro-
priate medication use by the elderly. Results of a US consensus
panel of experts. Arch Intern Med 1997; 163: 2716–4.
3. Hanlon JT, Schmader KE, Ruby CM, Weinberger M. Sub-
optimal prescribing in older inpatients and outpatients. J Am
Geriatr Soc 2001; 49: 200–9.
4. Simonson W, Feinberg JL. Medication-related problems in the
elderly: defining the issues and identifying solutions. Drugs
Aging 2005; 22: 559–69.
5. Spinewine A, Schmader KE, Barber N et al. Appropriate pre-
scribing in elderly people: how well can it be measured and
optimised? Lancet 2007; 370: 173–84.
6. Lindley CM, TullyMP, Paramsothy V, Tallis RC. Inappropriate
medication is a major cause of adverse drug reactions in elderly
patients. Age Ageing 1992; 21: 294–300.
7. Gallagher P, Barry P, Ryan C, Hartigan I, O’Mahony D. Inap-
propriate prescribing in an acutely ill population of elderly
patients as determined by Beers’ criteria. Age Ageing 2008; 37:
96–101.
8. Klarin I, Wimo A, Fastbom J. The association of inappropriate
drug use with hospitalisation and mortality: a population based
study of the very old. Drugs Aging 2005; 22: 69–82.
9. Lau DT, Kasper JD, Potter DE, Lyles A, Bennett RG. Hos-
pitalization and death associated with potentially inappropri-
ate medication prescriptions among elderly nursing home resi-
dents. Arch Intern Med 2005; 165: 68–74.
10. Gurwitz, JH, Field TS, Avorn J et al. Incidence and preventabil-
ity of adverse drug events in nursing homes. Am J Med 2000;
109: 87–94.
11. Zuckerman IH, Langenberg P, Baumgarten M et al. Inappro-
priate drug use and risk of transition to nursing homes among
community-dwelling older adults. Med Care 2006; 44: 722–30.
12. Fick DM, Waller JL, Maclean JR et al. Potentially inappropriate
medication use in a Medicare managed care population: asso-
ciation with higher costs and utilization. J Manag Care Pharm
2001; 7: 407–13.
13. Laroche ML, Charmes JP, Boutheir F, Merle L. Inappropriate
medications in theElderly. ClinPharmacolTher 2009; 85: 94–7.
14. Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D.
STOPP (Screening Tool of Older Persons’ Prescriptions) and
START (Screening Tool to Alert Doctors to Right Treatment):
consensus validation. Int J Clin Pharmacol Ther 2008; 46: 72–
83.
15. Gallagher P, O’Mahony D. STOPP (Screening Tool of Older
Persons’ potentially inappropriate Prescriptions): application to
acutely ill elderly patients and comparison with Beers’ criteria.
Age Ageing 2008; 37: 673–9.
16. Barry P, Gallagher P, Ryan C, O’Mahony D. START (Screen-
ing Tool to Alert doctors to Right Treatment). An evidence-
based screening tool to detect prescribing omissions in elderly
patients. Age Ageing 2007; 36: 628–31.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance
from serum creatinine. Nephron 1976; 16: 31–41.
18. Levey AS, Bosch JP, Lewis JB et al. Modification of Diet in
Renal Disease Study Group. A more accurate method to assess
glomerular filtration rate from serum creatinine: a new predic-
tion equation. Ann Intern Med 1999; 130: 461–70.
19. Levey AS, Green T, Kusek JW et al. A simplified equation to
predict glomerular filtration rate from serum creatinine. J Am
Soc Nephrol 2000; 11(Suppl): 155A.
20. Levey AS, Coresh J, Greene T et al. Using standardized serum
creatinine values in the modification of diet in renal disease
study equation for estimating glomerular filtration rate. Ann
Intern Med 2006; 145: 247–54.
21. Spruill WJ, Wade WE, Cobb HH. Comparison of estimated
glomerular filtration rate with estimated creatinine clearance
in the dosing of drugs requiring adjustments in elderly patients
with declining renal function.Am JGeriatr Pharmacother 2008;
6: 153–60.
22. Lamb EJ, Webb MC, O’Riordan SE. Using the modification
of diet in renal disease (MDRD) and Cockcroft and Gault
equations to estimate glomerular filtration rate (GFR) in older
people. Age Ageing 2007; 36: 689–92.
23. Landis JR,KockGG. Themeasurement of observer agreement
for categorical data. Biometrics 1977; 33: 159–74.
24. Cicchetti DV, Feinstein AR. High agreement but low kappa:
II. Resolving the paradoxes. J Clin Epidemiol 1990: 43: 551–8.
doi: 10.1093/ageing/afp058
Published electronically 12 May 2009
Vitamin D supplementation and type 2
diabetes: a substudy of a randomised
placebo-controlled trial in older people
(RECORD trial, ISRCTN 51647438)
SIR—Studies in animals show that vitamin D deficiency is
associated with impaired insulin sensitivity, and that insulin
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